Halozyme Therapeutics (HALO) - חוב לטווח ארוך להון

Halozyme Therapeutics (HALO) specializes in developing drug delivery systems. This daily price chart reflects the impact of a strategy centered on licensing innovations to global behemoths, which minimizes regulatory risks. Returns are based on partner payments for the use of its oncology platform, reaching 12.51. The business relies on the legal protection of intellectual property in the US and Europe, remaining outside the zone of geopolitical conflicts.

The long-term debt-to-equity ratio measures the proportion of liabilities with a maturity exceeding one year within the equity structure, determining the business's level of dependence on external borrowing. Analyzing the current long-term debt-to-equity figure allows for an assessment of the financial stability of Halozyme Therapeutics (HALO), whose partner royalty model minimizes bankruptcy risks even amidst disruptions in international supply chains.